KYBORA is an experienced global advisory firm that maintains close direct connections with the top 20 market leaders through regular updates and networking
KYBORA is happy to announce that it will sponsor the Bio Latin America Conference again this year. https://biolatinamerica.com/sponsors/ Taking place in Sao Paulo on September 3rd and 4th 2019, Bio Latin America is a must attend event that gathers many of the key players in the pharma and biotech industry in Latin America. KYBORA looks forward to […]
“If you are a U.S. company that does not yet have a China strategy…you need to get moving or risk missing out on a potentially big market,” Brad Loncar, CEO of Loncar Investments, wrote after attending this year’s China Healthcare Investment Conference. Trip reports like these are rolling in, reaffirming what is becoming more and […]
KYBORA is pleased to announce that it has successfully helped its client STADA Arzneimittel AG license Xlucane – a Ranibizumab (Lucentis) biosimilar to Bausch Health. This latest transaction reinforces KYBORA’s capability in delivering complex cross border transactions working with leading global pharmaceutical companies. “We are seeing an increase in the number of biosimilar deals around […]
KYBORA is pleased to announce that Anton Leshchenko has joined its team as Managing Director, responsible for expanding KYBORA’s operations in Russia, CIS/CEE, and Africa. Anton is a senior executive with 18+ years of life science and medical disposables experience with turn around and value addition achievements in territory management and BD&L (both in-/ out-license, […]
KYBORA is pleased to announce that Rainer Wulf has joined Kybora as a new member of the advisory board. Rainer is a Senior Executive with 30+ years of experience in the pharmaceutical industry, most of them in international positions, starting in sales and followed by Restructuring/Optimization of Sales Organizations, leadership positions in Marketing up to […]
